Highlights of ASH in North America

Join the world’s leading hematology experts at Highlights of ASH in North America, a two-day program offered in multiple locations that highlights the most influential research presented at the latest ASH annual meeting. Registration is now open! New York, New York | January 10-11, 2025 Seattle, Washington | January 10-11, 2025 Chicago, Illinois | January 17-18, 2025 Washington D.C. | January 31-February 1, 2025 By attending Highlights of ASH, you will get a comprehensive review of significant scientific

Read the full article here

Source: www.hematology.org

Categories: Oncologists1, General Medicine News

Tags: ASH24,MedTwitter

Tweets with this article

ASH

The breakthrough science of #ASH24 is coming to a city near you! Join leading experts to translate insights from standout abstracts into actionable strategies for your patients. Learn more about Highlights of ASH and our early bird discount! https://t.co/2GDtlN4Bsf #MedTwitter https://t.co/pXEi2BbLxP

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Key PointsDaratumumab plus chemotherapy may effectively bridge children and young adults with relapsed/refractory T-cell ALL/LL to HSCT.No new safety conce

Blood Journal November 26, 2024

FDA approves revumenib for r/r acute leukemia with a KMT2A translocation – The Cancer Letter

FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in…

The Cancer Letter November 26, 2024

Welcome! You are invited to join a webinar: Post-ASH 2024 CLL highlights webinar. After registering, you will receive a confirmation email about joining the webinar.

Join us to watch leading CLL experts present summaries on the most significant abstracts from ASH 2024 followed by interactive panel discussions debating current clinical…

VJHemOnc November 26, 2024

Related Articles